Wyeth’s worldwide animal health division recently reported a revenue increase of 12 percent to $313 million for the second quarter ended June 30. Year to date, the company reported a revenue increase of 6 percent to $590 million.
The increases were primarily due to higher sales of poultry products and livestock products driven by Zulvac bluetongue vaccine as well as the favorable impact of foreign exchange. Higher sales of companion animal products, including ProMeris flea and tick products, contributed to the second quarter revenue increase. Partially offsetting these increases were lower sales of equine products.
Overall, Wyeth reported net income of $1.12 billion on revenue of $5.95 billion for its second quarter, compared to net income of $1.2 billion on revenue of $5.65 billion in the year-ago period.
Year to date, the company reported net income of $2.32 billion on revenue of $11.66 billion, compared to net income of $2.45 billion on revenue of $11.02 billion.
Wyeth is the parent company of Fort Dodge Animal Health, which is based in Overland Park, Kan.